These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38588973)

  • 21. Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy.
    McCarthy MW
    Clin Pharmacokinet; 2020 May; 59(5):567-573. PubMed ID: 32009210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications.
    Ghazi IM; El Nekidy WS; Sood A; Dulku A; Patel R; Patel K; Li P
    Clin Ther; 2020 Mar; 42(3):475-485. PubMed ID: 32139175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
    Fratoni AJ; Kois AK; Gluck JA; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2024 May; 79(5):1118-1125. PubMed ID: 38517465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Gueny ME; Sahm DF
    J Antimicrob Chemother; 2019 Aug; 74(8):2284-2288. PubMed ID: 31086960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
    Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P; Bovo F; Bussini L; Lazzarotto T; Amadesi S; Bartoletti M; Viale P; Ambretti S
    J Antimicrob Chemother; 2022 May; 77(6):1570-1577. PubMed ID: 35373297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
    Girón RM; Ibáñez A; Gómez-Punter RM; Alarcón T
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):46-49. PubMed ID: 35488826
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia.
    Patel M; Bellanti F; Daryani NM; Noormohamed N; Hilbert DW; Young K; Kulkarni P; Copalu W; Gheyas F; Rizk ML
    Clin Transl Sci; 2022 Feb; 15(2):396-408. PubMed ID: 34704389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial.
    Kim JW; Chung J; Choi SH; Jang HJ; Hong SB; Lim CM; Koh Y
    Crit Care; 2012 Feb; 16(1):R28. PubMed ID: 22336530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
    Norrby SR; Finch RG; Glauser M
    J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic equivalence of generic imipenem/cilastatin for therapy of infections at Siriraj Hospital.
    Piyasirisilp S; Premprawat W; Thamlikitkul V
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S117-25. PubMed ID: 20364566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.
    Lob SH; Hoban DJ; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2018 Dec; 15():12-19. PubMed ID: 29857057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.
    Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
    J Glob Antimicrob Resist; 2018 Dec; 15():140-147. PubMed ID: 30071354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Lob SH; Hackel MA; Kazmierczak KM; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
    Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.
    Barnes MD; Bethel CR; Alsop J; Becka SA; Rutter JD; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530851
    [No Abstract]   [Full Text] [Related]  

  • 40. Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019.
    Lob SH; Hackel MA; Young K; Motyl MR; Sahm DF
    Diagn Microbiol Infect Dis; 2021 Aug; 100(4):115421. PubMed ID: 34082265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.